Efficacy of Spironolactone on Survival in Dogs with Naturally Occurring Mitral Regurgitation Caused by Myxomatous Mitral Valve Disease

Abstract

Spironolactone added to conventional cardiac therapy decreases the risk of reaching the primary endpoint (ie, cardiac-related death, euthanasia, or severe worsening) in dogs with moderate to severe MR caused by MMVD.

Keywords

Canine; Clinical trial; Evidence based medicine; Heart failure

Published in

Journal of Veterinary Internal Medicine
2010, volume: 24, number: 2, pages: 331-341
Publisher: WILEY-BLACKWELL PUBLISHING, INC

SLU Authors

• Häggström, Jens

  • Department of Clinical Sciences, Swedish University of Agricultural Sciences
    

UKÄ Subject classification

Animal and Dairy Science
Veterinary Science

Publication identifier

• DOI: https://doi.org/10.1111/j.1939-1676.2009.0467.x

Permanent link to this page (URI)

https://res.slu.se/id/publ/48529